Back
Compare AU
Compare QUAL vs. DRUG
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the VanEck MSCI International Quality ETF (QUAL) and the Betashares Global Healthcare Currency Hedged ETF (DRUG). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
QUAL | DRUG | |
|---|---|---|
Popularity | Medium | Low |
Pearlers invested | 1,489 | 74 |
Median incremental investment | $993.50 | $735.27 |
Median investment frequency | Monthly | Monthly |
Median total investment | $3,785.44 | $2,083.20 |
Average age group | > 35 | > 35 |
Key Summary
QUAL | DRUG | |
|---|---|---|
Strategy | QUAL's key objective is to invest in high-quality companies that have outperformed the market over the long term compared to global equity benchmarks. | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. The ETF currently has 177.71m in AUM and 55 holdings. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. |
Top 3 holdings | Microsoft Corp (6.07 %) Meta Platforms Inc Class A (5.50 %) Apple Inc (5.44 %) | AUD - AUSTRALIA DOLLAR (0 %) BRL - BRAZILIAN REAL (0 %) CHF - SWISS FRANC (0 %) |
Top 3 industries | Information Technology (44.94 %) Communication Services (29.45 %) Financials (8.21 %) | Other (75.91 %) Communication Services (33.53 %) Health Care (23.80 %) |
Top 3 countries | United States (76.41 %) Switzerland (5.61 %) United Kingdom of Great Britain and Northern Ireland (4.19 %) | United States (69.91 %) Switzerland (10.93 %) United Kingdom of Great Britain and Northern Ireland (7.38 %) |
Management fee | 0.4 % | 0.57 % |
Key Summary
QUAL | DRUG | |
|---|---|---|
Issuer | VanEck | BetaShares |
Tracking index | MSCI World ex Australia Quality Index - AUD | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD |
Asset class | ETF | ETF |
Management fee | 0.4 % | 0.57 % |
Price | $64.16 | $9.30 |
Size | $9.216 billion | $177.334 million |
10Y return | 250.98 % | 97.45 % |
Annual distribution yield (5Y) | 2.54 % | 1.82 % |
Market | ASX | ASX |
First listed date | 31/10/2014 | 08/08/2016 |
Purchase fee | $6.50 | $6.50 |
Community Stats
QUAL | DRUG | |
|---|---|---|
Popularity | Medium | Low |
Pearlers invested | 1,489 | 74 |
Median incremental investment | $993.50 | $735.27 |
Median investment frequency | Monthly | Monthly |
Median total investment | $3,785.44 | $2,083.20 |
Average age group | > 35 | > 35 |
Pros and Cons
QUAL | DRUG | |
|---|---|---|
Pros |
| |
Cons |
|
QUAL | DRUG |
|---|---|
Higher exposure to US market | Lower exposure to US market |
Lower management fee | Higher management fee |
Higher price growth | Lower price growth |
Higher distribution yield | Lower distribution yield |